Propranolol, a phosphatidate phosphohydrolase inhibitor, also inhibits protein kinase C

Silvano Sozzani, David E. Agwu, Charles E. McCall, Joseph T. O'Flaherty, Jeffrey D. Schmitt, Jonathan D. Kent, Linda C. McPhail

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Propranolol, a β-adrenergic receptor antagonist, also inhibits phosphatidate phosphohydrolase, the enzyme that converts phosphatidic acid into diacylglycerol. This latter effect has prompted recent use of propranolol in studies examining the importance of diacylglycerol and phosphatidic acid in cellular signalling events. Here, we show that propranolol is also an inhibitor of protein kinase C. At concentrations ≥ 20 μM, propranolol reduced [3H]phorbol dibutyrate binding (IC50 = 200 μM) and phorbol myristate acetate-stimulated superoxide anion release (IC50 = 130 μM) in human neutrophils. Scatchard analysis showed that propranolol lowers the number of phorbol diester binding sites without significantly affecting their affinity. In vitro kinetic analysis, performed in a mixed micellar assay with protein kinase C purified from human neutrophils, suggested a competitive inhibition of propranolol with the cofactor phosphatidylserine. Complex kinetic patterns were observed with respect to diacylglycerol and ATP, approximating competitive and noncompetitive inhibition, respectively. Taken together, these results suggest that the drug interacts at the level of the regulatory domain of the enzyme. Fifty % inhibition occurred at ∼150 μM propranolol. Similar levels of inhibition were obtained using exogenous (histone) and endogenous (p47-phox, a NADPH oxidase component) substrates. Protein kinase C-α and protein kinase C-β two protein kinase C isozymes present in human neutrophils, were inhibited by propranolol in a comparable manner. In the range of concentrations tested (30-1000 μM), neither cAMP-dependent protein kinase nor neutrophil protein tyrosine kinases were affected. The racemic form of propranolol and the (+) and the (-) stereoisomers were equally active, and other β-adrenergic receptor antagonists (pindolol) and agonists (isoproterenol) were inactive. This suggests that the inhibitory action of propranolol on protein kinase C is related to the amphipathic nature of the drug rather than to its β-adrenergic receptor blocking ability. Analogs of propranolol were synthesized and found to be more potent protein kinase C inhibitors, with IC50 values in the 10-20 μM range. We conclude that the ability of propranolol to inhibit both protein kinase C and PA phosphohydrolase complicates interpretation of results when this drug is used in signal transduction studies. In addition, propranolol may be a useful prototype for the synthesis of new protein kinase C inhibitors.

Original languageEnglish
Pages (from-to)20481-20488
Number of pages8
JournalJournal of Biological Chemistry
Volume267
Issue number28
Publication statusPublished - Oct 5 1992

Fingerprint

Phosphatidate Phosphatase
Propranolol
Protein Kinase C
Diglycerides
Neutrophils
Inhibitory Concentration 50
Phosphatidic Acids
Adrenergic Antagonists
Protein C Inhibitor
Protein Kinase Inhibitors
Pharmaceutical Preparations
Cell signaling
Pindolol
Signal transduction
Adrenergic Agonists
Stereoisomerism
Kinetics
NADPH Oxidase
Phosphatidylserines
Phorbol Esters

ASJC Scopus subject areas

  • Biochemistry

Cite this

Sozzani, S., Agwu, D. E., McCall, C. E., O'Flaherty, J. T., Schmitt, J. D., Kent, J. D., & McPhail, L. C. (1992). Propranolol, a phosphatidate phosphohydrolase inhibitor, also inhibits protein kinase C. Journal of Biological Chemistry, 267(28), 20481-20488.

Propranolol, a phosphatidate phosphohydrolase inhibitor, also inhibits protein kinase C. / Sozzani, Silvano; Agwu, David E.; McCall, Charles E.; O'Flaherty, Joseph T.; Schmitt, Jeffrey D.; Kent, Jonathan D.; McPhail, Linda C.

In: Journal of Biological Chemistry, Vol. 267, No. 28, 05.10.1992, p. 20481-20488.

Research output: Contribution to journalArticle

Sozzani, S, Agwu, DE, McCall, CE, O'Flaherty, JT, Schmitt, JD, Kent, JD & McPhail, LC 1992, 'Propranolol, a phosphatidate phosphohydrolase inhibitor, also inhibits protein kinase C', Journal of Biological Chemistry, vol. 267, no. 28, pp. 20481-20488.
Sozzani S, Agwu DE, McCall CE, O'Flaherty JT, Schmitt JD, Kent JD et al. Propranolol, a phosphatidate phosphohydrolase inhibitor, also inhibits protein kinase C. Journal of Biological Chemistry. 1992 Oct 5;267(28):20481-20488.
Sozzani, Silvano ; Agwu, David E. ; McCall, Charles E. ; O'Flaherty, Joseph T. ; Schmitt, Jeffrey D. ; Kent, Jonathan D. ; McPhail, Linda C. / Propranolol, a phosphatidate phosphohydrolase inhibitor, also inhibits protein kinase C. In: Journal of Biological Chemistry. 1992 ; Vol. 267, No. 28. pp. 20481-20488.
@article{710bbaac122d424db78ef07dc31d65c0,
title = "Propranolol, a phosphatidate phosphohydrolase inhibitor, also inhibits protein kinase C",
abstract = "Propranolol, a β-adrenergic receptor antagonist, also inhibits phosphatidate phosphohydrolase, the enzyme that converts phosphatidic acid into diacylglycerol. This latter effect has prompted recent use of propranolol in studies examining the importance of diacylglycerol and phosphatidic acid in cellular signalling events. Here, we show that propranolol is also an inhibitor of protein kinase C. At concentrations ≥ 20 μM, propranolol reduced [3H]phorbol dibutyrate binding (IC50 = 200 μM) and phorbol myristate acetate-stimulated superoxide anion release (IC50 = 130 μM) in human neutrophils. Scatchard analysis showed that propranolol lowers the number of phorbol diester binding sites without significantly affecting their affinity. In vitro kinetic analysis, performed in a mixed micellar assay with protein kinase C purified from human neutrophils, suggested a competitive inhibition of propranolol with the cofactor phosphatidylserine. Complex kinetic patterns were observed with respect to diacylglycerol and ATP, approximating competitive and noncompetitive inhibition, respectively. Taken together, these results suggest that the drug interacts at the level of the regulatory domain of the enzyme. Fifty {\%} inhibition occurred at ∼150 μM propranolol. Similar levels of inhibition were obtained using exogenous (histone) and endogenous (p47-phox, a NADPH oxidase component) substrates. Protein kinase C-α and protein kinase C-β two protein kinase C isozymes present in human neutrophils, were inhibited by propranolol in a comparable manner. In the range of concentrations tested (30-1000 μM), neither cAMP-dependent protein kinase nor neutrophil protein tyrosine kinases were affected. The racemic form of propranolol and the (+) and the (-) stereoisomers were equally active, and other β-adrenergic receptor antagonists (pindolol) and agonists (isoproterenol) were inactive. This suggests that the inhibitory action of propranolol on protein kinase C is related to the amphipathic nature of the drug rather than to its β-adrenergic receptor blocking ability. Analogs of propranolol were synthesized and found to be more potent protein kinase C inhibitors, with IC50 values in the 10-20 μM range. We conclude that the ability of propranolol to inhibit both protein kinase C and PA phosphohydrolase complicates interpretation of results when this drug is used in signal transduction studies. In addition, propranolol may be a useful prototype for the synthesis of new protein kinase C inhibitors.",
author = "Silvano Sozzani and Agwu, {David E.} and McCall, {Charles E.} and O'Flaherty, {Joseph T.} and Schmitt, {Jeffrey D.} and Kent, {Jonathan D.} and McPhail, {Linda C.}",
year = "1992",
month = "10",
day = "5",
language = "English",
volume = "267",
pages = "20481--20488",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "28",

}

TY - JOUR

T1 - Propranolol, a phosphatidate phosphohydrolase inhibitor, also inhibits protein kinase C

AU - Sozzani, Silvano

AU - Agwu, David E.

AU - McCall, Charles E.

AU - O'Flaherty, Joseph T.

AU - Schmitt, Jeffrey D.

AU - Kent, Jonathan D.

AU - McPhail, Linda C.

PY - 1992/10/5

Y1 - 1992/10/5

N2 - Propranolol, a β-adrenergic receptor antagonist, also inhibits phosphatidate phosphohydrolase, the enzyme that converts phosphatidic acid into diacylglycerol. This latter effect has prompted recent use of propranolol in studies examining the importance of diacylglycerol and phosphatidic acid in cellular signalling events. Here, we show that propranolol is also an inhibitor of protein kinase C. At concentrations ≥ 20 μM, propranolol reduced [3H]phorbol dibutyrate binding (IC50 = 200 μM) and phorbol myristate acetate-stimulated superoxide anion release (IC50 = 130 μM) in human neutrophils. Scatchard analysis showed that propranolol lowers the number of phorbol diester binding sites without significantly affecting their affinity. In vitro kinetic analysis, performed in a mixed micellar assay with protein kinase C purified from human neutrophils, suggested a competitive inhibition of propranolol with the cofactor phosphatidylserine. Complex kinetic patterns were observed with respect to diacylglycerol and ATP, approximating competitive and noncompetitive inhibition, respectively. Taken together, these results suggest that the drug interacts at the level of the regulatory domain of the enzyme. Fifty % inhibition occurred at ∼150 μM propranolol. Similar levels of inhibition were obtained using exogenous (histone) and endogenous (p47-phox, a NADPH oxidase component) substrates. Protein kinase C-α and protein kinase C-β two protein kinase C isozymes present in human neutrophils, were inhibited by propranolol in a comparable manner. In the range of concentrations tested (30-1000 μM), neither cAMP-dependent protein kinase nor neutrophil protein tyrosine kinases were affected. The racemic form of propranolol and the (+) and the (-) stereoisomers were equally active, and other β-adrenergic receptor antagonists (pindolol) and agonists (isoproterenol) were inactive. This suggests that the inhibitory action of propranolol on protein kinase C is related to the amphipathic nature of the drug rather than to its β-adrenergic receptor blocking ability. Analogs of propranolol were synthesized and found to be more potent protein kinase C inhibitors, with IC50 values in the 10-20 μM range. We conclude that the ability of propranolol to inhibit both protein kinase C and PA phosphohydrolase complicates interpretation of results when this drug is used in signal transduction studies. In addition, propranolol may be a useful prototype for the synthesis of new protein kinase C inhibitors.

AB - Propranolol, a β-adrenergic receptor antagonist, also inhibits phosphatidate phosphohydrolase, the enzyme that converts phosphatidic acid into diacylglycerol. This latter effect has prompted recent use of propranolol in studies examining the importance of diacylglycerol and phosphatidic acid in cellular signalling events. Here, we show that propranolol is also an inhibitor of protein kinase C. At concentrations ≥ 20 μM, propranolol reduced [3H]phorbol dibutyrate binding (IC50 = 200 μM) and phorbol myristate acetate-stimulated superoxide anion release (IC50 = 130 μM) in human neutrophils. Scatchard analysis showed that propranolol lowers the number of phorbol diester binding sites without significantly affecting their affinity. In vitro kinetic analysis, performed in a mixed micellar assay with protein kinase C purified from human neutrophils, suggested a competitive inhibition of propranolol with the cofactor phosphatidylserine. Complex kinetic patterns were observed with respect to diacylglycerol and ATP, approximating competitive and noncompetitive inhibition, respectively. Taken together, these results suggest that the drug interacts at the level of the regulatory domain of the enzyme. Fifty % inhibition occurred at ∼150 μM propranolol. Similar levels of inhibition were obtained using exogenous (histone) and endogenous (p47-phox, a NADPH oxidase component) substrates. Protein kinase C-α and protein kinase C-β two protein kinase C isozymes present in human neutrophils, were inhibited by propranolol in a comparable manner. In the range of concentrations tested (30-1000 μM), neither cAMP-dependent protein kinase nor neutrophil protein tyrosine kinases were affected. The racemic form of propranolol and the (+) and the (-) stereoisomers were equally active, and other β-adrenergic receptor antagonists (pindolol) and agonists (isoproterenol) were inactive. This suggests that the inhibitory action of propranolol on protein kinase C is related to the amphipathic nature of the drug rather than to its β-adrenergic receptor blocking ability. Analogs of propranolol were synthesized and found to be more potent protein kinase C inhibitors, with IC50 values in the 10-20 μM range. We conclude that the ability of propranolol to inhibit both protein kinase C and PA phosphohydrolase complicates interpretation of results when this drug is used in signal transduction studies. In addition, propranolol may be a useful prototype for the synthesis of new protein kinase C inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0026783578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026783578&partnerID=8YFLogxK

M3 - Article

VL - 267

SP - 20481

EP - 20488

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 28

ER -